

Meeting Agenda	
Division:	Iowa Medicaid Enterprise Quality Improvement Organization (QIO)
Meeting Title:	Clinical Advisory Committee (CAC)
Facilitator:	Bill Jagiello, D.O.
Location:	Go To Webinar and conference call: (562)247-8422, access code: 466-337-327
Date:	January 15, 2021
Time:	1:00 p.m. – 4:00 p.m.

Meeting Objectives
<p>The purpose of the CAC is to increase the efficiency, quality and effectiveness of the Medicaid healthcare system. The CAC provides a process for physician and other healthcare provider contributions to promote quality care, member safety, cost effectiveness and positive physician and provider relations through discussion about Medicaid benefits and healthcare services.</p> <p>The CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decision to the Department of Human Services (DHS) for the Iowa Medicaid program.</p>

Meeting Participants	
Name	Organization
Bill Jagiello, D.O.	IME
Mark Randleman, D.O.	IME
Tami Lichtenberg	IME personnel
Becky Carter	IME personnel
Cassie Reece	IME personnel
Jennifer Ober	IME personnel
Dr. Paul Mulhausen	Iowa Total Care
Dr. Leslie Schechtman	Amerigroup
Lisa Roush	IME personnel
Teri Stolte	IME personnel
Paula Motsinger	DHS
Anna Ruggle	DHS
Dr. Polly Ferguson- Pediatric Rheumatology	
Dr. Stephen Mandler- Psychiatry	
Dr. Andrea Silver- Family Practice	
Dr. Dennis Zachary- Family Practice	

Dr. Dana Danley- Family Practice	
Dr. Kathy Lange- Family Practice	
Clarice Blanchard, PA-C- Family Practice/Emergency Medicine	
Sherry Buske ARNP- Family Practice	
Dr. Alexandra Hubbell- Family Practice	
Dawn Bina	MT Pharma
Emily Rogers	Iowa Total Care
Hannah Baer	Coalition for Access to Prenatal Screening for non-invasive prenatal testing
Heather Thompson	Lundbeck Seattle BioPharmaceuticals
Jane Juusola	GeneDx
Matthew Wright	Artia Solutions
Jennifer Stoffel	Janssen Scientific
Susie Moroney	Novartis
Angela Freeman	
Angie Brym	
Ashley Svenson	
Jennifer O'Neill	
Patrick Murphy	
Steve Isaki	
Catherine Kloft	
David Tritsch	
John Schillo	
Joseph Conoshenti	
Brian Peterson	
Mark Kaiser	
Devki Nagar	
Dot Guccione	
Gary Behrens	
Karen Floeder	
Lisa Tracz	
Rebecca Murphy	

Agenda Topics	Responsible Party
Public Comment Period	Guests
New Business: <ol style="list-style-type: none"> 1. Update on COVID vaccines and monoclonal antibodies. 2. Replacement recommendations for Sherry Buske, ARNP and Dr. Andrea Silvers, second term expires after the April meeting. 	Dr. Jagiello
Consent Agenda <ol style="list-style-type: none"> 1. Approval of minutes from October meeting 2. High Frequency Chest Wall Oscillators (HFCWO) 3. Botulinum Toxins 4. Fecal Microbiota Transplantation 5. Pegloticase (Krystexxa)- Pulled, to be reviewed at the next meeting. 6. Pembrolizumab (Keytruda) 7. Genetic testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRACA2) 8. Bariatric Surgery (CoE/MBSAQIP) 	Dr. Jagiello
Criteria Review <ol style="list-style-type: none"> 1. Environmental Modification-Adaptive Devices 2. Adakveo **NEW 3. Lutathera **NEW 4. Tecartus **NEW 5. Yescarta **NEW 6. Spravato **NEW 7. Tisagenlecleucel (Kymriah) 8. Trodelvy **NEW 9. Vyepiti **NEW 10. Non-Invasive Prenatal Testing for Aneuploidy Using Cell Free DNA 11. Chromosomal Microarray Analysis **NEW 12. Whole Exome Sequencing **NEW 13. Lung Transplant 	Dr. Jagiello
Upcoming Meetings April 16, 2021 July 16, 2021 October 15, 2021	Dr. Jagiello
Adjournment	Dr. Jagiello

Public comment period:

We opened up the meeting for discussion to anyone that wanted to comment. No response was received.

New Business:

1. Update on COVID vaccines and monoclonal antibodies. Dr. Jagiello- (Handout: 2207-MC-FFS_COVID-19_Vaccines_&_Monoclonal_Antibodies) This will be sent out to the committee members and posted on the website. Medicaid released an Informational Letter on administering CPT codes and guidance for those offices that may be administering the COVID vaccine to Medicaid patients. And also the administration of monoclonal antibodies, proper coding. These may be underutilized.
2. Replacement recommendations for Sherry Buske, ARNP and Dr. Andrea Silvers, second term expires after the April meeting. Dr. Jagiello- They have filled two three year terms, we will be looking for replacements for their roles. We are asking our committee members to offer suggestions for their replacements. We will need to know their specialty, geographic location and whether they are affiliated with a larger healthcare system. We strive to balance metropolitan to rural, and specialty and primary care.

Consent Agenda:

Dr. Jagiello- Explained that the consent agenda is a procedural tool to allow us to review policies that don't require any changes as a group for a decision to approve or deny. Pegloticase (Krystexxa) will be pulled from this list, additional information has been received and we will raise it again at the April meeting. Any comments or wish to change to the above list was requested, no responses received. Comments from the public were also requested and none received. Dr. Zachary motioned to approve accepting the consent agenda as presented. Dr. Lange seconded, all approved. The motion carried.

Criteria Review:

1. Environmental Modification-Adaptive Devices- Lisa Roush, subject matter expert at IME (Iowa Medicaid Enterprise) presented changes to the descriptive narrative, the criteria #3-5, updated the materials list necessary for review and references. Dr. Hubbell motioned to approve accepting the policy as amended. Dr. Ferguson seconded, all approved. The motion carried.
2. Adakveo **NEW- Dr. Jagiello discussed the development of the policy, the sources used and how other plans managed the policies. Public comments were taken from Susie Moroney. She asked that we reconsider the initial approval for 6 months and consultation with hematologist with expertise in diagnosis and management of sickle cell disease to just hematologist. Dr. Hubbell agreed given the amount of rural area we serve in Iowa. Criteria #3 was amended to remove 'with expertise in the diagnosis and management of sickle cell disease'. Under continuation of treatment, #1- When initial request continues to meet all criteria for treatment- to be removed. Matthew Wright spoke regarding the length of time for approval. The committee agreed to 6 months for the length of time for initial approval, Dr. Jagiello offered to consider additional information on this point and we could re-evaluate at the April meeting if needed. Dr. Ferguson offered to present research. The committee voted to approve with stated amendments and look at it again in April, Dr. Silvers motioned to approve, Sherry Buske seconded, all approved. The motioned carried. The committee agreed at a later date to approve as amended with no further review needed.
3. Lutathera **NEW- Dr. Jagiello discussed the development of the policy. Dr. Silvers motioned to approve as presented, Dr. Ferguson seconded, all approved. The motioned carried.

4. Tecartus **NEW- Dr. Jagiello discussed the development of the policy. Dr. Zachary motioned to approve as presented. Dr. Silvers seconded, all approved. The motion carried.
5. Yescarta **NEW- Dr. Jagiello discussed the development of the policy. Sherry Buske motioned to approve as presented. Dr. Zachary seconded, all approved. The motion carried.
6. Spravato **NEW- Dr. Jagiello discussed the development of the policy. Dr. Stephen Mandler and Jennifer Stoffel offered further discussion around the criteria. She will send information to Dr. Jagiello for review. Dr. Jagiello will look over the criteria as it pertains to suicidal ideation. It was determined that we would approve it as written and look at it again at the April meeting. Dr. Ferguson motioned to approve as presented. Dr. Hubbell seconded, all approved. The motion carried.
7. Tisagenlecleucel (Kymriah)- Susie Moroney asked if this could be administered both inpatient and outpatient, Dr. Jagiello stated we will look into that during our coding process. No changes were made at this time. Dr Ferguson motioned to approve as presented. Dr. Silvers seconded, all approved. The motion carried.
8. Trodelvy **NEW- Dr. Jagiello discussed the development of the policy. Clarice Blanchard motioned to approve as presented. Sherry Buske seconded, all approved.
9. Vyepiti **NEW- Dr. Jagiello discussed the development of the policy. Heather Thomson discussed medication overuse headache more in depth. Dr. Jagiello asked the committee if they would approve the policy as written and go back and review further. Dr. Zachary motioned to approve the policy as presented. Dr. Mandler seconded the motion, all approved. The motion carried.
10. Non-Invasive Prenatal Testing for Aneuploidy Using Cell Free DNA- Hannah Baer recommended that this be offered to all pregnant women. Dr. Hubbell asked for clarification on genetic counseling and who that would need to be provided by. Dr. Danley offered questions on the triple and quadruple screen. Dr. Zachary motioned to approve as presented. Dr. Hubbell seconded the motioned, all approved. The motion carried.
11. Chromosomal Microarray Analysis **NEW- Dr. Jagiello discussed the development of the policy. Dr. Ferguson motioned to approve as presented. Dr. Zachary seconded the motion, all approved. The motion carried.
12. Whole Exome Sequencing **NEW- Dr. Jagiello discussed the development of the policy. It was discussed that the age to test should be increased. Dr. Jagiello asked Dr. Ferguson to offer research on how it applies to a larger population in response to her recommendation to lower the age. Dr. Zachary motioned to approve as presented. Sherry Buske seconded, all approved. The motion carried.
13. Lung Transplant- Dr. Jagiello stated this would be tabled. This policy was approved without changes by email and will be reviewed again in October after noted revisions are sent to our Subject Matter Expert to consider.

Dr. Jagiello noted that our next meeting will be held April 16th and the meeting was adjourned.